Diadema Partners LP Cassava Sciences Inc Put Options Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
Put Options
1 transactions
Others Institutions Holding SAVA
# of Institutions
190Shares Held
16.4MCall Options Held
3.49MPut Options Held
8.08M-
Black Rock Inc. New York, NY3.22MShares$8.69 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.51MShares$6.79 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.72 Million0.0% of portfolio
-
State Street Corp Boston, MA997KShares$2.69 Million0.0% of portfolio
-
Ubs Group Ag931KShares$2.51 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $108M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...